New prostate cancer drug may cause fewer side effects than current option
NCT ID NCT05526248
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested two drugs, darolutamide and enzalutamide, in 28 men with prostate cancer that had returned after initial treatment. The goal was to see how each drug affects testosterone levels and side effects like breast tenderness. Darolutamide may cause fewer of these side effects because it doesn't enter the brain as easily. The study is small and early, so more research is needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Darolutamide (Nubeqa) and Enzalutamide
What this could lead to
If successful, this study could show that darolutamide causes fewer side effects like breast tenderness while still controlling prostate cancer, offering a better-tolerated treatment option.
What could go wrong
This is a small, early-phase study with only 28 participants, so results may not apply to all patients. It compares two drugs but does not test against a placebo or standard therapy, limiting what can be concluded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOCHEMICALLY RECURRENT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center - Oncology
Boston, Massachusetts, 02215, United States
-
Central Ohio Urology Group - Gahanna
Gahanna, Ohio, 43230, United States
-
Mass General Cancer Center
Boston, Massachusetts, 02114-2696, United States
-
Memorial Sloan Kettering Cancer Center New York - Main Campus
New York, New York, 10065, United States
-
Unio Specialty Care - Urology - Sherman Oaks
Sherman Oaks, California, 91411, United States